Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Thymagen cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established Thymagen cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. In the preoperative study, intranasal Thymogen was given for 7 days before surgery 12.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Thymagen combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Thymagen cycle length?
No. Human studies administered Thymagen for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of Thymagen?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Thymagen dosing reference Full research page

References

  1. Effect of thymagen, thymalin and vilosen on the cAMP and cGMP levels and phosphodiesterase activity in spleen lymphocytes during sensitization and anaphylactic shock (in Russian) Ukrainskii Biokhimicheskii Zhurnal. 1991
  2. Novel platform for the preparation of synthetic orally active peptidomimetics with hemoregulating activity. II. Hemosuppressor activity of 2,5-diketopiperazine-based cyclopeptides International Immunopharmacology. 2020
  3. Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity ChemMedChem. 2016
  4. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line International Journal of Molecular Sciences. 2022
  5. Immunotherapy of pulmonary tuberculosis (in Russian) Problemy Tuberkuleza. 1998
  6. PubMed query for "thymagen" (1 record, a 1991 Russian-language paper that uses the spellings thymagen and thymogen for the same agent) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
  7. PubMed query for "thymogen" (103 records under the NLM supplementary concept “thymogen”) PubMed / NCBI Entrez (U.S. National Library of Medicine). 2026
  8. ClinicalTrials.gov registry query for "thymagen" (0 studies returned) ClinicalTrials.gov (U.S. National Library of Medicine). 2026
  9. openFDA Drug Label API query for "thymagen" (no approved human drug labeling for a peptide of this name) U.S. Food and Drug Administration / openFDA. 2026
  10. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) U.S. Food and Drug Administration. 2026
  11. World Anti-Doping Code International Standard — Prohibited List 2026 (effective 1 January 2026) World Anti-Doping Agency. 2026
  12. [Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity] Adv Gerontol. 2011
  13. [Immunomodulating activity of thymogen in acute pancreatitis] Vopr Pitan. 2000
  14. [Thymogen in the complex treatment of inflammatory diseases of the female genital system] Akush Ginekol (Mosk). 1992
  15. [Repair stimulator alpha-glutamyl-tryptophan in the complex therapy of chronic atrophic gastritis: results of histological examination] Arkh Patol. 2023
  16. [Endoscopic and morphometric analysis of the reduction of acute inflammatory process in the gastric mucosa after therapy with Regasthym Gastro] Ter Arkh. 2023
  17. [The effect of thymogen on the state of immunity in destructive pulmonary tuberculosis] Voen Med Zh. 1999